Arcturus Therapeutics Holdings/ARCT

$30.43

-6.48%
-
1D1W1MYTD1YMAX

About Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Ticker

ARCT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joseph Payne

Employees

180

Headquarters

San diego, United States

ARCT Metrics

BasicAdvanced
$819.03M
Market cap
-
P/E ratio
-$1.16
EPS
2.62
Beta
-
Dividend rate
$819.03M
2.61547
$43.81
$17.52
458.17K
4.715
-6.76%
-10.83%
-8.86%
4.91
2.931
2.941
-19.03%
-1,952.16%
159.56%

What the Analysts think about ARCT

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
122.25% upside
High $140.00
Low $18.00
$30.43
Current price
$67.63
Average price target

ARCT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-37.98% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$30.8M
-31.71%
Net income
$-11.7M
-27.78%
Profit margin
-37.98%
5.73%

ARCT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 67.75%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$1.87
-$1.98
-$0.61
-$0.32
-
Expected
$0.06
-$0.21
-$1.69
-$0.99
-$1.05
Surprise
3,029.71%
839.5%
-63.94%
-67.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Arcturus Therapeutics Holdings stock?

Arcturus Therapeutics Holdings (ARCT) has a market cap of $819.03M as of April 14, 2024.

What is the P/E ratio for Arcturus Therapeutics Holdings stock?

The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of April 14, 2024.

Does Arcturus Therapeutics Holdings stock pay dividends?

No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Arcturus Therapeutics Holdings dividend payment date?

Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.

What is the beta indicator for Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Arcturus Therapeutics Holdings stock price target?

The target price for Arcturus Therapeutics Holdings (ARCT) stock is $67.63, which is 122.25% above the current price of $30.43. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Arcturus Therapeutics Holdings stock

Buy or sell Arcturus Therapeutics Holdings stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing